Arthritis News and Research

Latest Arthritis News and Research

Lilly Phase I multiple myeloma study affirms potential of LY2127399-bortezomib combination

Eli Lilly and Company announced Phase I data on LY2127399, a human monoclonal antibody that neutralizes B-cell activating factor (BAFF), for use in combination with bortezomib in patients with previously-treated multiple myeloma.

21 May 2011

African Americans with SLE have higher antibody response to influenza vaccination: Study

New research shows that African Americans with systemic lupus erythematosus had a higher antibody response to influenza vaccination than European American patients.

21 May 2011

EMA CHMP recommends positive opinion for marketing authorization of Amgen's XGEVA

Amgen today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended a positive opinion for the marketing authorization of XGEVA (denosumab) for the prevention of skeletal-related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with bone metastases from solid tumors.

20 May 2011

Osteoarthritis directly linked to low-fat, high-carb food

Osteoarthritis is a degenerative joint disease and the most common cause of disability today. It was once considered a problem of the old but it is now commonly diagnosed in those as young as the mid-twenties and early thirties. According to the Arthritis Foundation, about four million, quality-adjusted life years are lost due to knee osteoarthritis alone.

20 May 2011

CEL-SCI initiates global Multikine Phase III trial for head and neck cancer in Russia

CEL-SCI Corporation announced today that it has commenced its global Phase III clinical trial for Multikine®, the Company's flagship immunotherapy, in Russia at the State Budgetary Healthcare Institution of Sverdlovsk Region - Sverdlovsk Regional Oncology Center in Ekaterinburg, Russia.

20 May 2011

Medical food resolves metabolic syndrome and cardiovascular risk factors

Researchers at the University of Florida and Metagenics Inc. today announced that a program consisting of a breakthrough medical food combined with a low-glycemic, Mediterranean-style diet is almost twice as effective as one of the best diets alone for lowering risk factors for cardiovascular disease, the leading cause of death in the U.S.

19 May 2011

Thermo Fisher Scientific to acquire Phadia for €2.47 billion

Thermo Fisher Scientific Inc., the world leader in serving science, today announced that it has signed a definitive agreement to acquire Phadia, a global leader in allergy and autoimmunity diagnostics, from European private equity firm Cinven, for €2.47 billion (or approximately $3.5 billion) in cash.

From Thermo Fisher Scientific Inc. 19 May 2011

Online program helps people to manage chronic pain

There is good news for the 76 million Americans who experience chronic pain including migraine, back pain, fibromyalgia and arthritis. A new study reveals that an online, self-paced chronic pain management program reduces the physical and psychological burdens of this debilitating condition.

19 May 2011

Free NYU Physician iPad app now available in iTunes store

NYU Langone Medical Center, one of the nation's premier academic medical centers, announced today the magazine of NYU School of Medicine, NYU Physician, is now available as a free iPad app in the iTunes App Store.

19 May 2011

Nektar to present new NKTR-102 Phase 2 clinical data in multiple cancers at ASCO annual meeting

Nektar Therapeutics today announced that new Phase 2 clinical data for NKTR-102, Nektar's lead oncology candidate being evaluated in multiple cancer indications, have been selected for presentation at the 47th Annual Meeting of the American Society of Clinical Oncology being held June 3-7, 2011 in Chicago, Illinois.

19 May 2011

Amgen announces primary results from XGEVA Phase 3 trial in castrate-resistant prostate cancer

Amgen today announced primary results of a pivotal Phase 3 trial demonstrating that XGEVA significantly increased bone metastasis-free survival for more than four months in men with castrate-resistant metastatic prostate cancer that has not yet spread to bone.

18 May 2011

CEL-SCI initiates Multikine Phase III trial for head and neck cancer in Canada

CEL-SCI Corporation announced today that it has commenced its global Phase III clinical trial for Multikine, the Company's flagship immunotherapy, in Canada at St. Joseph's Healthcare - Hamilton, Ontario.

18 May 2011

ProBioGen, Life Technologies' new cell line development kits now available for biologic drug production

Life Technologies Corporation and ProBioGen AG today announced the availability of Gibco Freedom Cell Line Development Kits, a new line of royalty-free products that integrate cells, reagents, culture media and protocols to bring simplicity and flexibility, eliminating up to two months in the earliest stages of new biological drug development.

17 May 2011

Anti-inflammatory drug celecoxib reacts with protein and induces liver cancer cells to commit suicide

The anti-inflammatory drug celecoxib, known by the brand name Celebrex, triggers liver cancer cell death by reacting with a protein in a way that makes those cells commit suicide, according to a new study.

17 May 2011

Pediatric researchers find potential tools for controlling cytokine storm

By analyzing complex interactions of the immune system in an animal study, pediatric researchers have found potential tools for controlling a life-threatening condition called a cytokine storm that may strike children who have juvenile arthritis and other autoimmune diseases.

17 May 2011

CEL-SCI initiates Multikine Phase III trial for head and neck cancer in Poland

CEL-SCI Corporation announced today that it has commenced its global Phase III clinical trial for Multikine, the Company's flagship immunotherapy, at the Centrum Onkologii - Instytut im. Marii Skłodowskiej-Curie, Warsaw, Poland, the first clinical site in Poland and the first center in the EU.

13 May 2011

PCR testing for B. burgdorferi bacteria in joint fluid may confirm Lyme arthritis diagnosis

New research shows that polymerase chain reaction testing for Borrelia burgdorferi DNA—the spirochetal bacteria transmitted by deer ticks—in joint fluid may confirm the diagnosis of Lyme arthritis, but is not a reliable indicator for active joint infection in patients whose arthritis persists after antibiotic therapy. Findings of this study are published in Arthritis & Rheumatism, a journal of the American College of Rheumatology.

13 May 2011

GSK, AstraZeneca and University of Manchester create new collaborative centre for inflammation research

The University of Manchester, GlaxoSmithKline and AstraZeneca announce today the creation of the Manchester Collaborative Centre for Inflammation Research, a unique collaboration to establish a world-leading translational centre for inflammatory diseases. The project starts out with an initial investment of -5M from each partner over a three year period.

From The University of Manchester 12 May 2011

Journal of Rheumatology publishes positive results from Cimzia Phase III trial in RA

UCB announced today results from a post hoc analysis of the RAPID 1 study published in the Journal of Rheumatology. The results suggest moderate to severe rheumatoid arthritis patients treated with Cimzia, the only approved PEGylated anti-TNF, together with methotrexate, achieved a rapid response associated with improved long-term outcomes one year after treatment began.

11 May 2011

Scleroderma is an independent determinant for coronary calcification, study suggests

A new study by researchers in Hong Kong suggests that systemic sclerosis is an independent determinant for moderate to severe coronary calcification or atherosclerosis.

11 May 2011

Arthritis News and Research

Latest Arthritis News and Research

Lilly Phase I multiple myeloma study affirms potential of LY2127399-bortezomib combination

African Americans with SLE have higher antibody response to influenza vaccination: Study

EMA CHMP recommends positive opinion for marketing authorization of Amgen's XGEVA

Osteoarthritis directly linked to low-fat, high-carb food

CEL-SCI initiates global Multikine Phase III trial for head and neck cancer in Russia

Medical food resolves metabolic syndrome and cardiovascular risk factors

Thermo Fisher Scientific to acquire Phadia for €2.47 billion

Online program helps people to manage chronic pain

Free NYU Physician iPad app now available in iTunes store

Nektar to present new NKTR-102 Phase 2 clinical data in multiple cancers at ASCO annual meeting

Amgen announces primary results from XGEVA Phase 3 trial in castrate-resistant prostate cancer

CEL-SCI initiates Multikine Phase III trial for head and neck cancer in Canada

ProBioGen, Life Technologies' new cell line development kits now available for biologic drug production

Anti-inflammatory drug celecoxib reacts with protein and induces liver cancer cells to commit suicide

Pediatric researchers find potential tools for controlling cytokine storm

CEL-SCI initiates Multikine Phase III trial for head and neck cancer in Poland

PCR testing for B. burgdorferi bacteria in joint fluid may confirm Lyme arthritis diagnosis

GSK, AstraZeneca and University of Manchester create new collaborative centre for inflammation research

Journal of Rheumatology publishes positive results from Cimzia Phase III trial in RA

Scleroderma is an independent determinant for coronary calcification, study suggests

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Arthritis News and Research

Latest Arthritis News and Research

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Newsletters you may be interested in